GENE ONLINE|News &
Opinion
Blog

KRAS
Study Advocates Cautious Application of CRISPR in Designing Therapeutics
2021-11-22
Genomic Profiling Reveals Multiple Resistance Mechanisms of Cancers Against KRAS Inhibitors
2021-06-25
We Have a Winner! Amgen Grabs First FDA Nod in the Race for Undruggable KRAS
2021-05-30
R&D
Targeting KRAS Mutants: Advances in Drugging the “Undruggable”
2021-04-19
Investors Bet $120 Million on Ikena Oncology’s Cancer Therapies
2021-01-06
Mirati’s Successful Targeting of the “Undruggable” Shapes Up Regulatory Showdown with Amgen
2020-10-28
R&D
Amgen’s KRAS Inhibitor Registers Long-Lasting Performance in Solid Tumors
2020-09-27
New Frontiers in Therapeutics
2020-07-25Partner
AACR 2020: Targeting the KRAS Pathway – Old Protein, New Approaches
2020-04-30
Amgen’s Efficacy of AMG 510 to KRAS G12C Mutant Critical for Future Directions and Business Investments
2019-10-02
LATEST
Kaiser’s Data Breach: 13.4 Million Affected in Healthcare Conglomerates Privacy Crisis
2024-04-26
Mechanisms of Allograft Rejection: Insights from Behind the Scenes
2024-04-25
ImmunityBio’s ANKTIVA® Granted FDA Approval: Breakthrough IL-15 Receptor Agonist First-in-Class for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
2024-04-24
Takeda, Astellas, and Sumitomo Mitsui Banking Declare Agreement For Early Drug Discovery Program Incubation in Joint Venture
2024-04-23
Ochre Bio Announces Partnership with Boehringer Ingelheim to Develop Novel Regenerative Treatments for Patients with Advanced Liver Disease
2024-04-22
Earth Day Awareness: Hospitals Embrace Sustainability Efforts
2024-04-22
WHO Raises Alarm: Bird Flu Threat to Humans an ‘Enormous Concern’
2024-04-19
EVENT
2024-04-27
2024 Biomedical Final Pitch Competition
Room DA1620, Dana Building, Dana-Farber Cancer Institute, 99 Jimmy Fund Way, Boston, MA 02115
Scroll to Top